Literature DB >> 14526434

Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization.

Xiaofeng Liao1, Jilin Yi, Xingrui Li, Zhifang Yang, Wei Deng, Geng Tian.   

Abstract

In order to investigate the changes of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in residual hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE), the expression levels of VEGF and bFGF expression in specimens surgically removed from 48 HCC patients were detected by immunohistochemical methods, and staining intensity of VEGF and bFGF was assessed by a computer-assisted image-analyzer. Among the 48 patients, 25 underwent partial hepatectomy alone (single operating group), and 23 were subjected to second stage surgical resection after TACE (TACE group). The results showed that the average absorbance value (A) of VEGF was higher in TACE group than that in single operating group (0.152 +/- 0.021 vs 0.131 +/- 0.012, P < 0.01). The Average A of bF-GF in TACE group was 0.127 +/- 0.023, higher than in single operating group (0.111 +/- 0.016, P < 0.05). These results suggested that TACE of HCC can up-regulate the expression of VEGF and bFGF in HCC tissues possibly due to anoxia and ischemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14526434     DOI: 10.1007/bf02829514

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  9 in total

1.  Study on the changes in microvessel density in hepatocellular carcinoma following transcatheter arterial chemoembolization.

Authors:  J Yi; X Liao; Z Yang; X Li
Journal:  J Tongji Med Univ       Date:  2001

2.  High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma.

Authors:  Y Seo; H Baba; T Fukuda; M Takashima; K Sugimachi
Journal:  Cancer       Date:  2000-05-15       Impact factor: 6.860

3.  Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.

Authors:  J Zhou; Z Y Tang; J Fan; Z Q Wu; X M Li; Y K Liu; F Liu; H C Sun; S L Ye
Journal:  J Cancer Res Clin Oncol       Date:  2000-01       Impact factor: 4.553

4.  Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma.

Authors:  X M Li; Z Y Tang; L X Qin; J Zhou; H C Sun
Journal:  J Exp Clin Cancer Res       Date:  1999-12

5.  Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study.

Authors:  B C Song; Y H Chung; J A Kim; H C Lee; H K Yoon; K B Sung; S H Yang; K Yoo; Y S Lee; D J Suh
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

6.  Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.

Authors:  Hitoshi Yoshiji; Shigeki Kuriyama; Junichi Yoshii; Yasuhide Ikenaka; Ryuichi Noguchi; Daniel J Hicklin; James Huber; Toshiya Nakatani; Hirohisa Tsujinoue; Koji Yanase; Hiroo Imazu; Hiroshi Fukui
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

7.  Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma.

Authors:  K W Kim; S K Bae; O H Lee; M H Bae; M J Lee; B C Park
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

8.  Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization.

Authors:  T C Liou; S C Shih; C R Kao; S Y Chou; S C Lin; H Y Wang
Journal:  J Hepatol       Date:  1995-11       Impact factor: 25.083

9.  Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma.

Authors:  K Jinno; M Tanimizu; I Hyodo; Y Nishikawa; Y Hosokawa; T Doi; H Endo; T Yamashita; Y Okada
Journal:  J Gastroenterol       Date:  1998-06       Impact factor: 7.527

  9 in total
  5 in total

1.  Value of the portal venous phase in evaluation of treated hepatocellular carcinoma following transcatheter arterial chemoembolisation.

Authors:  A Lam; D Fernando; C C Sirlin; M Nayyar; S C Goodwin; D K Imagawa; C Lall
Journal:  Clin Radiol       Date:  2017-08-02       Impact factor: 2.350

2.  Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study.

Authors:  Carolyn D Britten; Antoinette S Gomes; Zev A Wainberg; David Elashoff; Rafael Amado; Yan Xin; Ronald W Busuttil; Dennis J Slamon; Richard S Finn
Journal:  BMC Cancer       Date:  2012-01-14       Impact factor: 4.430

Review 3.  The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma.

Authors:  Kang Liu; Xu-Li Min; Juan Peng; Ke Yang; Lin Yang; Xiao-Ming Zhang
Journal:  J Clin Med Res       Date:  2016-02-27

4.  Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models.

Authors:  Da-Yong Zhou; Jie Qin; Jian Huang; Feng Wang; Guo-Peng Xu; Yan-Tian Lv; Ji-Bin Zhang; Li-Ming Shen
Journal:  Oncol Lett       Date:  2017-08-03       Impact factor: 2.967

5.  Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model.

Authors:  Johanna Maria Mijntje van Breugel; Jean-François Geschwind; Sahar Mirpour; Lynn Jeanette Savic; Xuchen Zhang; Rafael Duran; MingDe Lin; Milena Miszczuk; Eleni Liapi; Julius Chapiro
Journal:  Theranostics       Date:  2019-05-27       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.